Alex started Symmetron Limited in London with an objective to provide bespoke, quality work and a comprehensive assessment of health care technologies in the UK, Europe and internationally. Since 2005 he provides training in health economics and TreeAge in Europe and Australia, at ISPOR meetings or at regular public training sessions organised by Symmetron Limited or TreeAge Inc.

His experience in health economics covers a wide range of therapeutic areas including oncology, diabetes, rheumatoid arthritis, venous thromboembolism, cardiovascular disease, gynaecology, ADHD, bipolar disorder, multiple sclerosis, antiviral treatments, diagnostics, and various applications of mechanical devices.

Alex has a strong analytical background and a high level of experience in a variety of economic modelling methods; cohort analysis, stochastic analysis, individual simulation models etc. By applying appropriate mathematical modelling and statistical techniques, Alex is interested in illustrating the potential of the studied interventions and ensuring a successful reimbursement.

Alex has led the design and development of international health economic projects and supported reimbursement submissions to regulatory authorities in England and Wales (NICE), Scotland (SMC), Canada (CDR), Sweden (TLV), Netherlands (CVZ), Ireland (NCPE), Norway (SLV), Australia (PBAC), Finland, Belgium, Switzerland, Austria, France, Portugal, Germany, Spain, Italy, Poland, Estonia, US, South Korea, Brazil, Argentina and many more. Alex has also played an integral role in the dissemination and presentation of the research with oral presentations to international conferences and publications to peer reviewed journals.

Stacey returned to academia to complete her PhD in Health Sciences from the University of York. Her thesis analysed outcome measurements in the economic evaluation of drug misuse interventions. This involved providing a comprehensive methodological critique of existing evaluation methods, for which she conducted systematic reviews and analyses of individual patient level data. During her PhD Stacey also developed a decision analytic model for a drug testing in schools programme, which was sponsored by the Joseph Rowntree Foundation. Whilst at York, she also attended the advanced modelling methods course provided by the Centre of Health Economics.

She is literate in using STATA software and through her studies, has performed a critical appraisal for the economic evaluation of the cost effectiveness of heptavalent conjugate pneumococcal vaccine. She has also completed a review of the suitability of different outcome measures for use in economic evaluation for schizophrenia, looking specifically at the performance of EQ-5D and the condition specific measure, S-QoL. Further to this, she has also conducted freelance work for a consultancy firm. This work included reviewing and extracting data from NICE technology appraisals.

Since she joined Symmetron she has been involved in systematic reviews of utility studies and health economic modelling.

After graduating with honours, Laura joined the National Clinical Guideline Centre, based at the Royal College of Physicians, where she worked as a health economist and later as a senior health economist developing evidence-based clinical guidelines for the National Institute for Health and Clinical Excellence (NICE). As a senior health economist, she was responsible for conducting systematic reviews of economic evidence and developing original decision models to assess the cost-effectiveness of relevant prevention, diagnostic and/or treatment strategies. She worked closely with clinicians, patient representatives and systematic reviewers to ensure the approach to modelling was valid, the methods were of high quality and the results were useful for decision-making.

Her work for NICE includes an economic evaluation of strategies for the diagnosis of chest pain; an analysis of cost-effective intervention sequences for the treatment of nocturnal enuresis; evaluation of single and combination pharmacological therapies in the management of the epilepsies; assessment of strategies for the management of psoriasis. Laura also has experience developing network meta-analyses of direct and indirect comparisons, having undertaken this type of evidence synthesis in therapeutic areas such as nocturnal enuresis, epilepsy and psoriasis.

After graduating, Corinne spent two years working for MEDCOST, a health economics company in Paris, before moving to Sydney, Australia, where she joined M-TAG (now part of the IMS HEOR group) in 2001. She was appointed Biostatistics Manager in 2006, and as such was in charge of the management of all the statistical projects for both the Australian and English offices. During her time at M-TAG, Corinne was involved in numerous national and international health economics projects such as submissions to reimbursement authorities, burden of illness studies, multi-country conjoint analyses, meta-analyses and indirect comparisons and price defence studies.

Since July 2007, Corinne has been working as an independent senior biostatistician, based in Ireland, offering her services to health economics and outcomes research groups and pharmaceutical companies.